Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management

Study acronym: LDL-ALERT
StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Brigham and Women's Hospital to Brigham and Women's Hospital Show 5 more changesShow less
    • Study completion pushed from Jun 30, 2026 to Dec 30, 2026
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
    • Eligibility criteria expanded, about 4 words
    • Study description expanded, about 3 words
  2. Study completion date: Sep 30, 2025 to Jun 30, 2026v5
  3. Study completion date: Sep 30, 2024 to Sep 30, 2025v4
  4. Study completion date: Dec 30, 2023 to Sep 30, 2024v3
  5. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Sep 30, 2023 to Dec 30, 2022
    • Site details revised
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values. The 400 patients will be comprised of 200 in the "Hospitalized Patient Cohort" and 200 in the "Outpatient Clinic Cohort." The allocation ratio will be 1:1 for an electronic alert-based CDS (EPIC BPA) notification versus no notification.
Trial Details
NCT Number NCT05088759
Lead Sponsor Brigham and Women's Hospital
Conditions
(from sponsor)		 Hyperlipemia, Mixed, ASCVD
Related terms Hyperlipidemias, Hyperlipoproteinemia Type V
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov